Equity of access to pathological diagnosis and bronchoscopy for lung cancer in Aotearoa New Zealand

被引:0
作者
Gurney, Jason [1 ]
Davies, Anna [1 ]
Stanley, James [1 ]
Whitehead, Jesse [2 ]
Cameron, Laird [3 ]
Costello, Shaun [4 ]
Dawkins, Paul [5 ]
Koea, Jonathan [6 ]
机构
[1] Univ Otago, Dept Publ Hlth, 23a Mein St, Wellington 6037, New Zealand
[2] Univ Waikato, Te Ngira Inst Populat Res, Hamilton, New Zealand
[3] Te Whatu Ora Te Toka Tumai Auckland, Auckland, New Zealand
[4] Te Whatu Ora Southern, Southern Blood & Canc Unit, Dunedin, New Zealand
[5] Te Whatu Ora Cty Manukau, Resp Serv, Auckland, New Zealand
[6] Te Whatu Ora Waitemata, Gen Surg Serv, Auckland, New Zealand
关键词
MAORI; MANAGEMENT; COMORBIDITY; DISPARITIES; IMPACT; STAGE;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Maori are less likely to survive their lung cancer once diagnosed, but it remains unclear whether this is partially driven by poorer access to best-practice diagnostic services. Methods: We examined all lung cancer registrations in Aotearoa New Zealand between 2007-2019 (n=27,869) linked to national administrative health datasets and further stratified by ethnicity, tumour type and stage of disease. Using descriptive and regression analyses, we compared ethnic groups in terms of the basis of diagnosis (e.g., histology, cytology), receipt of bronchoscopy and travel distance and time to access bronchoscopy. Results: We found no differences in access to a pathological diagnosis between ethnic groups regardless of cancer type or stage. We found that M & amacr;ori within the cohort were marginally more likely to access bronchoscopy than the majority European group; however, we also found that M & amacr;ori had lower odds of living close to the location of their bronchoscopy, and correspondingly higher odds of living 100-200km (adjusted odds ratio [adj. OR] 1.46, 95% confidence interval [CI] 1.26-1.69) or more than 200km away (1.36, 95% CI 1.15-1.61) than Europeans. Conclusion: Interventions that aim to further support M & amacr;ori to overcome the systematic and cumulative disadvantages in access to cancer care should be broadly supported and resourced.
引用
收藏
页码:40 / 58
页数:19
相关论文
共 30 条
[1]   Incidence and management of hepatocellular carcinoma among Maori and non-Maori New Zealanders [J].
Chamberlain, Joshua ;
Sarfati, Diana ;
Cunningham, Ruth ;
Koea, Jonathan ;
Gurney, Jason ;
Blakely, Tony .
AUSTRALIAN AND NEW ZEALAND JOURNAL OF PUBLIC HEALTH, 2013, 37 (06) :520-526
[2]  
Collins LG, 2007, AM FAM PHYSICIAN, V75, P56
[3]   Social and geographical factors affecting access to treatment of lung cancer [J].
Crawford, S. M. ;
Sauerzapf, V. ;
Haynes, R. ;
Zhao, H. ;
Forman, D. ;
Jones, A. P. .
BRITISH JOURNAL OF CANCER, 2009, 101 (06) :897-901
[4]   Experiences of Maori of Aotearoa New Zealand's public health system: a systematic review of two decades of published qualitative research [J].
Graham, Rebekah ;
Masters-Awatere, Bridgette .
AUSTRALIAN AND NEW ZEALAND JOURNAL OF PUBLIC HEALTH, 2020, 44 (03) :193-200
[5]   Equity of travel required to access first definitive surgery for liver or stomach cancer in New Zealand [J].
Gurney, Jason ;
Whitehead, Jesse ;
Kerrison, Clarence ;
Stanley, James ;
Sarfati, Diana ;
Koea, Jonathan .
PLOS ONE, 2022, 17 (08)
[6]   Disparities in Cancer-Specific Survival Between Maori and Non-Maori New Zealanders, 2007-2016 [J].
Gurney, Jason ;
Stanley, James ;
McLeod, Melissa ;
Koea, Jonathan ;
Jackson, Chris ;
Sarfati, Diana .
JCO GLOBAL ONCOLOGY, 2020, 6 :766-774
[7]  
Gurney J, 2020, NEW ZEAL MED J, V133, P43
[8]   The impact of patient comorbidity on cancer stage at diagnosis [J].
Gurney, Jason ;
Sarfati, Diana ;
Stanley, James .
BRITISH JOURNAL OF CANCER, 2015, 113 (09) :1375-1380
[9]  
Gurney JK, 2022, NEW ZEAL MED J, V135, P23
[10]  
Gurney JK, 2020, NEW ZEAL MED J, V133, P77